文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

沙特阿拉伯神经肌肉与电诊断医学专家以及海湾合作委员会地区的神经肌肉专家关于重症肌无力诊断与管理的共识指南。

Consensus guidelines on the diagnosis and management of myasthenia gravis by the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine and neuromuscular specialists from the Gulf Cooperation Council region.

作者信息

Alshehri Ali Mohammed, Alanazy Mohammed H, Alabdali Majed, Abuzinadah Ahmad R, Alshareef Aysha, Abulaban Ahmad, AlRoughani Raed A, Abdulla Fatema Mohamed, Hassan Ali M A, Alhatou Mohammed Ibrahim, Almadani Abubaker, Alrukn Suhail Abdulla, Alsaadi Taoufik, Al Salti Abdullah Mohammed, Shatila Ahmed, Thakre Mona Chetan, Alyahya Mossaed, Alzahmi Fatmah, AlHajjar Lynn, Alsolaihim Alanood A, Alamro Mazen, Alotaibi Muteb Khidhran, Bushnag Areej Abdulrahman, Bamaga Ahmed K, Jumah Mohammed Al

机构信息

Neuroscience Center, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Department of Internal Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

出版信息

Ther Adv Neurol Disord. 2025 Jun 27;18:17562864251346333. doi: 10.1177/17562864251346333. eCollection 2025.

DOI:10.1177/17562864251346333
PMID:40584517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12205206/
Abstract

The introduction of numerous therapeutic advancements in the management of myasthenia gravis (MG) may add difficulties in clinical decision-making, especially when no recommendations tailored to the local context are available. For this reason, the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine (SANEM) chapter of the Saudi Neurology Society launched an initiative to discuss and agree on issues related to the management of MG in the Gulf Cooperation Council (GCC) region. An expert panel from all GCC countries (Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Qatar, and Oman) was formed to develop practical recommendations using the Delphi method to facilitate the management approach of MG and enhance patient outcomes.

摘要

重症肌无力（MG）治疗方面众多进展的引入可能会给临床决策带来困难，尤其是在没有适合当地情况的建议时。因此，沙特神经病学协会的沙特阿拉伯神经肌肉与电诊断医学（SANEM）分会发起了一项倡议，以讨论并就海湾合作委员会（GCC）地区MG管理相关问题达成共识。来自所有海湾合作委员会国家（沙特阿拉伯、阿拉伯联合酋长国、巴林、科威特、卡塔尔和阿曼）的一个专家小组成立，采用德尔菲法制定实用建议，以促进MG的管理方法并改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/246ab94ea130/10.1177_17562864251346333-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/7a14d70a65cb/10.1177_17562864251346333-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/c9af952f6edc/10.1177_17562864251346333-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/f93d8ee3696f/10.1177_17562864251346333-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/246ab94ea130/10.1177_17562864251346333-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/7a14d70a65cb/10.1177_17562864251346333-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/c9af952f6edc/10.1177_17562864251346333-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/f93d8ee3696f/10.1177_17562864251346333-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/246ab94ea130/10.1177_17562864251346333-fig4.jpg

相似文献

[1]
Consensus guidelines on the diagnosis and management of myasthenia gravis by the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine and neuromuscular specialists from the Gulf Cooperation Council region.

Ther Adv Neurol Disord. 2025-6-27

[2]
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.

Curr Med Res Opin. 2025-5

[3]
Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED].

Neurology. 2007-6-12

[4]
Human biomonitoring of environmental contaminants in Gulf Countries - current status and future directions.

Environ Res. 2023-11-1

[5]
Medical and surgical treatment for ocular myasthenia.

Cochrane Database Syst Rev. 2006-4-19

[6]
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Health Technol Assess. 2006-9

[7]
Internet addiction in Gulf countries: A systematic review and meta-analysis.

J Behav Addict. 2021-9-6

[8]
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.

Health Technol Assess. 2025-6-25

[9]
Intravenous immunoglobulin for myasthenia gravis.

Cochrane Database Syst Rev. 2003

[10]
Home treatment for mental health problems: a systematic review.

Health Technol Assess. 2001

本文引用的文献

[1]
Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis.

Front Immunol. 2024

[2]
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.

Lancet Neurol. 2024-3

[3]
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.

NEJM Evid. 2022-5

[4]
Guideline for the management of myasthenic syndromes.

Ther Adv Neurol Disord. 2023-12-26

[5]
Incidence and prevalence of neurological disorders in the United Arab Emirates: a systematic review.

BMC Neurol. 2023-11-3

[6]
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

Front Immunol. 2023

[7]
Myasthenic crisis.

Muscle Nerve. 2023-7

[8]
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.

J Neurol. 2023-8

[9]
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.

Lancet Neurol. 2023-5

[10]
Novel Immunotherapies for Myasthenia Gravis.

Immunotargets Ther. 2023-4-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索